Every DEF 14A that Cineverse Corp. (CNVS) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow CNVS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CNVS filings page.
Cineverse Corp. is calling a virtual special stockholder meeting on September 15, 2026 to seek approval under Nasdaq Listing Rule 5635(a) and (d) for issuing Class A common stock tied to its February 2026 IndiCue, Inc. acquisition and outstanding convertible notes. The IndiCue purchase price was $22,000,000, including $12,800,000 in cash at closing and up to $9,200,000 payable in cash or stock, plus potential stock- or cash-settled earnouts based on financial performance. Cineverse also issued $13,000,000 of convertible notes bearing 9% interest with a conversion price of $2.00 per share and related warrants mechanics. Approval would allow issuance of up to 21,805,701 shares at illustrative prices, and potentially more if earnout shares are priced below $1.93, causing substantial dilution and possible anti-takeover effects. If approval is not obtained, Cineverse may need to settle acquisition and note obligations in cash, which could pressure liquidity. A separate proposal would allow adjournment of the meeting to solicit additional proxies.
Cineverse Corp. (CNVS) filed Amendment No. 2 to its 2025 proxy, updating Proposal Four language about the 2017 Equity Incentive Plan. The plan now states a $1,000,000 annual cap on the aggregate value of Common Stock issuable to all non-employee directors. It also clarifies that each non-employee director is anticipated to receive a $90,000 restricted stock award after each annual meeting, valued using the trailing 20-day VWAP as of the meeting date, whether or not the proposal is approved.
Cineverse Corp. (CNVS) filed definitive additional proxy materials tied to its 2025 annual meeting set for November 20, 2025. The filing states it was made solely to include required interactive data; all other proxy details remain unchanged.
Stockholders will vote on electing four directors, an advisory say‑on‑pay, the frequency of future say‑on‑pay (the Board recommends 1 year), an amendment to the 2017 Equity Incentive Plan to increase authorized shares from 2,504,913 to 3,504,913, and ratification of EisnerAmper LLP as auditor for the year ending March 31, 2026.
Holders of record on September 24, 2025 may vote. 19,124,406 shares of Class A Common Stock were outstanding as of that date. The proxy outlines plan governance features (no evergreen, no repricing without stockholder approval, minimum one‑year vesting, clawback) and indicates non‑employee director equity awards valued at $90,000 annually (based on 20‑day VWAP) and $180,000 for new directors. CNVS last closed at $3.50 on September 24, 2025.
Cineverse Corp. outlines its 2017 Equity Incentive Plan governance and 2023–2025 executive and director compensation practices. The plan is administered by an independent Compensation Committee, has no evergreen replenishment, and caps aggregate director awards at 300,000 shares. Awards generally carry a minimum one-year vesting requirement (with a 5% exception), prohibit discounted options or repricings without stockholder approval, and are subject to the company's clawback policy.
Reported grants include 237,500 restricted stock awards and 237,500 restricted stock units to NEOs in fiscal 2025 (accounting for $1,501,000 of NEO CAP), and 150,000 restricted awards and 150,000 restricted units to the PEO in fiscal 2025 (accounting for $948,000 of the PEO CAP). Prior-year grants included 115,000 options in 2024 and 125,000 options in 2023 with multi-year vesting and ten-year option terms where noted. Non-employee director pay includes a $60,000 cash retainer, a $90,000 annual stock grant (trailing 20-day VWAP), committee fees, a $20,000 lead director fee, and a $180,000 new-director grant vesting over three years.